— New Early Adopter Program provides access to tools for improved student engagement and retention PHILADELPHIA, May 19, 2023 /PRNewswire/ — Wodify, a technology platform for fitness businesses, introduces the Early Adopter Program for jiu-jitsu. This unique program offers jiu-jitsu studio owners the opportunity to be among the first to revolutionize the industry with cutting-edge … Read more
TactiFlex™ Ablation Catheter, Sensor Enabled™, is the world’s first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation When used with Abbott’s EnSite™ X EP System, physicians have better visualization allowing for more accuracy and precision with the TactiFlex catheter, leading to reduced procedure times … Read more
Iconic Locations across the U.S. Shine the Light on Supporting Those Living with Food Allergies MCLEAN, Va., May 19, 2023 /PRNewswire/ — As part of FARE’s (Food Allergy Research & Education’s) ongoing work to raise awareness of food allergies, the organization sets aside one week in May as Food Allergy Awareness Week to bring the … Read more
Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ). Top-line data of the final analysis from Phase II to be announced in the second half of next year. SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEOs: … Read more
CHENGDU, Chine, 19 mai 2023 /PRNewswire/ — Le 17 mai 2023, le vaccin protéique COVID-19 recombinant bivalent (cellules Sf9) et le vaccin protéique trimérique COVID-19 recombinant trivalent (cellules Sf9) développés par WestVac Biopharma/West China Medical Center, de l’université du Sichuan, contre les variants XBB les plus récents en circulation, ont reçu l’« Approbation pour essai clinique du médicament » de l’Administration nationale … Read more
SEÚL, Corea del sur, 19 de mayo de 2023 /PRNewswire/ — Genome & Company (consejero delegado: Pae, Jisoo), desarrollador líder mundial de terapias de microbiomas, anunció que este ensayo de fase II (NCT05419362) continuará sin modificaciones para pasar a la segunda etapa, según el resultado positivo del análisis provisional. Usando una bacteria de una sola … Read more
Первая в своем роде: рекомбинантная мультивалентная белковая вакцина против COVID-19 от вариантов XBB производства WestVac Biopharma/Западно-китайского медицинского центра Сычуаньского университета была одобрена для клинических испытаний Национальным управлением медицинской продукции Китая. ЧЭНДУ, Китай, 19 мая 2023 г. /PRNewswire/ — 17 мая 2023 года рекомбинантная двухвалентная белковая вакцина против COVID-19 (клетки Sf9) и рекомбинантная трехвалентная тримерная белковая … Read more
CHENGDU, China, 19. Mai 2023 /PRNewswire/ — Am 17. Mai 2023 erhielten der rekombinante bivalente COVID-19-Protein-Impfstoff (Sf9-Zellen) und der rekombinante trivalente COVID-19-Protein-Impfstoff (Sf9-Zellen), die von WestVac Biopharma/ West China Medical Center, Sichuan University gegen die neuesten zirkulierenden XBB-Varianten entwickelt wurden, die “Genehmigung für klinische Versuche” von der National Medical Products Administration of China. Diese beiden … Read more
CHENGDU, China, 18 de mayo de 2023 /PRNewswire/ — El 17 de mayo de 2023, la vacuna proteica bivalente recombinante contra la COVID-19 (células Sf9) y la vacuna proteica trivalente recombinante contra la COVID-19 (células Sf9) desarrolladas por WestVac Biopharma/Centro Médico de China Occidental, Sichuan University, contra las variantes XBB más recientes, recibieron la “aprobación … Read more
CHENGDU, China, 18 de maio de 2023 /PRNewswire/ — Em 17 de maio de 2023, a vacina bivalente de proteína COVID-19 recombinante (células Sf9) e a vacina trivalente de proteína trímera COVID-19 recombinante (células Sf9) desenvolvidas pela WestVac Biopharma/West China Medical Center, da Universidade de Sichuan, contra as variantes XBB mais recentes em circulação, receberam … Read more